Is vortioxetine (Trintellix) an appropriate treatment option for body‑dysmorphic disorder?

Trintellix (Vortioxetine) is NOT Recommended for Body Dysmorphic Disorder

Vortioxetine should not be used for body dysmorphic disorder (BDD) as it has no evidence supporting its efficacy for this condition, and established first-line treatments with proven efficacy exist.

Why Vortioxetine is Inappropriate for BDD

No Evidence Base

• Vortioxetine (Trintellix) is FDA-approved exclusively for major depressive disorder (MDD), not BDD 1
• The drug label contains no indication, trials, or data for BDD treatment
• There have been no pharmacological trials in young people with BDD 2, and no trials in adults with BDD using vortioxetine

Established Treatment Guidelines Specify Different Medications

According to the most recent 2024 guidelines 2:

First-line pharmacotherapy for BDD consists of:

• Selective serotonin reuptake inhibitors (SSRIs) - specifically traditional SSRIs like fluoxetine, which has Level 1 evidence from placebo-controlled trials 3
• SSRIs should be used as second-line treatment (after CBT) for young people aged 12-18 years with moderate to severe BDD-related functional impairment who have not responded to CBT 2

The Evidence Supporting SSRIs (Not Vortioxetine):

• Fluoxetine demonstrated 53% response rate vs. 18% placebo response in the only placebo-controlled BDD trial (p=0.003) 3
• SSRIs show pooled effect size of SMD = -1.16 for depressive symptoms in BDD 4
• Both delusional and non-delusional BDD patients respond to SSRIs 3
• Clomipramine (an SRI) also shows efficacy 5

Critical Distinction: Vortioxetine is NOT a Traditional SSRI

While vortioxetine affects serotonin, it is a multimodal antidepressant with 5-HT3A and 5-HT7 receptor antagonism, 5-HT1B partial agonism, 5-HT1A agonism, and serotonin transporter inhibition 6. This mechanism differs substantially from traditional SSRIs that have demonstrated efficacy in BDD.

What You Should Use Instead

For BDD treatment, the evidence-based algorithm is:

1. First-line: Cognitive Behavioral Therapy (CBT) with exposure and response prevention 2

   • Large effect size (Cohen's d = 1.13 in adolescents) 2
   • Should involve family/carers and be developmentally adapted

2. Second-line or concurrent: Traditional SSRIs 2

   • Fluoxetine (strongest evidence) 3
   • Other SSRIs (sertraline, paroxetine, fluvoxamine, citalopram/escitalopram)
   • Higher doses and longer trials than typical MDD treatment are often required 7, 8

3. For treatment-resistant cases:

   • Switch to another SSRI 8
   • Consider clomipramine 5
   • SRI augmentation strategies 8

Critical Clinical Context

BDD is a high-risk psychiatric disorder with 11-44% of young people having attempted suicide 2. Using an unproven medication when evidence-based treatments exist could delay effective intervention and worsen outcomes, including increased suicide risk.

The comorbid depression often present in BDD (70% have comorbid diagnoses) 2 does not justify using vortioxetine, as traditional SSRIs treat both the BDD and depressive symptoms effectively 3, 4.

Bottom line: Use fluoxetine or another traditional SSRI with established BDD efficacy, not vortioxetine.